Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
    Meeting Abstract

    Solomon, B. J.; Martini, J. F.; Ou, S. H. I.; Chiari, R.; Soo, R. A.; Bearz, A.; Li, S.; Thurm, H.; Lin, C. C.; Riely, G. J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of crizotinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
    Meeting Abstract

    Moro-Sibilot, D.; Ahn, M. J.; Halmos, B.; Kim, D. W.; Riely, G. J.; Shaw, A. T.; Yang, P. C.; Lanzalone, S.; Polli, A.; Wilner, K. D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Mezquita, L.; Arbour, K.; Auclin, E.; Saravia, D.; Rizvi, H.; Hendriks, L.; Planchard, D.; Park, W.; Nadal, E.; Ruffinelli Rodriguez, J. C.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
    Meeting Abstract

    Ott, P. A.; Govindan, R.; Naing, A.; Friedlander, T. W.; Margolin, K.; Lin, J. J.; Bhardwaj, N.; Hellman, M. D.; Srinivasan, L.; Greshock, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Meeting Abstract

    Lassen, U. N.; Albert, C. M.; Kummar, S.; van Tilburg, C. M.; Dubois, S. G.; Geoerger, B.; Mascarenhas, L.; Federman, N.; Schilder, R. J.; Doz, F.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
    Meeting Abstract

    Besse, B.; Subbiah, V.; Drilon, A.; Shah, M.; Wirth, L. J.; Bauer, T. M.; Velcheti, V.; Lakhani, N.; Boni, V.; Solomon, B. J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Meeting Abstract

    Yoshino, T.; Iwata, H.; Tamura, K.; Takahashi, S.; Redfern, C.; Modi, S.; Doi, T.; Kawakami, H.; Taniguchi, H.; Takashima, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
    Meeting Abstract

    Rudin, C. M.; Pandha, H. S.; Gupta, S.; Zibelman, M. R.; Akerley, W.; Day, D.; Hill, A. G.; Sanborn, R. E.; O'Day, S. J.; Clay, T. D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Janne, P. A.; Yu, H. A.; Moro-Sibilot, D.; Goldberg, T.; Gu, X.; Li, J.; McGill, J.; Yu, C.; Slosberg, E.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
    Meeting Abstract

    Diamond, J. R.; Standifer, N.; Ascierto, M. L.; Morehouse, C.; Ghadially, H.; Canales, J. R.; Rebelatto, M. C.; Naidoo, J.; Mazzarella, L.; Patel, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save